April 20, 2020 - Press Releases
MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London, 20 April 2020 – Epsilogen (formerly IGEM Therapeutics), a global leader in the...
April 20, 2020 - Press Releases
MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer Investors commit to a further £3 million Series A2 financing of...
April 9, 2019 - Press Releases
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM Therapeutics’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E...
April 2, 2019 - Press Releases
Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of...
November 30, 2018 - Press Releases
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM Therapeutics to continue development of IgE therapeutic antibody portfolio and novel IgE-based platform technology London, November 30th, 2018 –...
October 15, 2018 - Press Releases
London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has won the “Best Start-up Biotech Company” award at the OBN Awards 2018...
August 23, 2018 - Press Releases
IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards London, 22 August 2018– IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to...
May 9, 2018 - Press Releases
£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM Therapeutics to progress second product candidate towards the clinic London, 9 May 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel...
